Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Nature Communications|December 9, 2025
Fragment-based discovery enables direct targeting of the melanoma oncogene MITFDeborah Castelletti, Jürgen Hinrichs, Goran Malojčić, et al.Nature|May 7, 2025
Targeting the SHOC2-RAS interaction in RAS-mutant cancersZachary J Hauseman, Frédéric Stauffer, Kim S Beyer, et al.Journal of Medicinal Chemistry|September 29, 2023
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid TumorsAlexander M Taylor, Bret R Williams, Fabrizio Giordanetto, et al.Nature Cancer|June 5, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistanceThijs J Hagenbeek, Jason R Zbieg, Marc Hafner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.Nature Biotechnology|May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse modelsMallika Singh, Anthony Lima, Rafael Molina, et al.The Journal of Pathology|May 22, 2012
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour modelsMallika Singh, Suzana S Couto, William F Forrest, et al.Nature Communications|June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer modelThijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.Pageof 4